Janartan

Valsartan/Hydrochlorothiazide, the active ingredient in Janartan, is an angiotensin II receptor blocker (ARB) / thiazide diuretic combination presented as an oral tablet for oral use. It treats hypertension in adult patients.

GNH USA supplies Janartan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Janartan, an ARB/thiazide diuretic combination, is used to manage high blood pressure and related cardiovascular risk. - Hypertension: lowers systolic and diastolic blood pressure in patients with essential hypertension. - Stage 2 hypertension: provides additional blood‑pressure reduction when monotherapy is insufficient. - Combination therapy: offers dual‑mechanism control for patients requiring more than one antihypertensive agent.

Common Side Effects: - Dizziness: transient light‑headedness, especially after the first doses. - Headache: mild to moderate intensity, often resolves with continued therapy. - Fatigue: feeling of tiredness without exertion. - Increased urination: due to the diuretic component. - Electrolyte imbalance: mild changes in potassium or sodium levels. - Mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe dehydration: marked fluid loss requiring medical attention. - Electrolyte disturbances: significant hyperkalemia, hyponatremia, or hypokalemia. - Acute kidney injury: sudden decline in renal function. - Angioedema: swelling of face, lips, tongue, or throat. - Severe hypotension: dangerous drop in blood pressure. - Allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy, consider the following precautions: - Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Renal function assessment: check serum creatinine and eGFR regularly. - Electrolyte surveillance: monitor potassium and sodium levels, especially in patients on other diuretics. - Hepatic impairment: use with caution in patients with liver disease. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Janartan may interact with several medicines. Major Interactions (Avoid): - Aliskiren: combined use can increase risk of renal impairment and hyperkalemia. - Lithium: may raise lithium concentrations, leading to toxicity. - ACE inhibitors or other ARBs: concurrent use raises hyperkalemia risk. - Potassium‑sparing diuretics: can cause dangerous hyperkalemia. - NSAIDs: may blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - Other thiazide diuretics: additive diuretic effect may cause dehydration. - Antihypertensive agents: may enhance blood‑pressure lowering, requiring dose adjustment. - CYP3A4 inhibitors (e.g., ketoconazole): can increase valsartan levels. - CYP3A4 inducers (e.g., rifampin): may reduce valsartan efficacy. - Antidiabetic drugs: blood‑glucose control may need closer monitoring.